SCHEMBL16828034

SCHEMBL16828034

CC(C)(C)OC(=O)N1CCC(C(=O)CN)CC1.Cc1ccc(S(=O)(=O)O)cc1

nearest known ligand 0.54

Known targets — ChEMBL curated mechanism

ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.54
GPR119 Q8TDV5 6/20 0.52
STS P08842 6/20 0.52
MMP13 P45452 1/20 0.51
EPHX2 P34913 1/20 0.48
MEN1 O00255 1/20 0.48
PTPRB P23467 1/20 0.47
PTPN11 Q06124 1/20 0.47
PTPN2 P17706 1/20 0.46
PTPN1 P18031 1/20 0.46
PTPN6 P29350 1/20 0.46
TP53 P04637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7396569 0.86 GPR119 (0.54) KMT2AGPR119STSMMP13MEN1
SCHEMBL14622828 0.83 HPGD (0.59) KMT2AGPR119STSMEN1PTPN2
SCHEMBL8632391 0.83 GPR119 (0.55) KMT2AGPR119STSMMP13MEN1
SCHEMBL9037340 0.79 GPR119 (0.53) KMT2AGPR119STSMMP13EPHX2
SCHEMBL32667357 0.79 KMT2A (0.60) KMT2AGPR119STSEPHX2MEN1
SCHEMBL10265584 0.78 GPR119 (0.57) KMT2AGPR119STSMMP13EPHX2
SCHEMBL23546383 0.77 GPR119 (0.60) KMT2AGPR119STSMMP13EPHX2
SCHEMBL1971128 0.76 GPR119 (0.47) KMT2AGPR119STSMMP13MEN1
SCHEMBL30693162 0.76 GPR119 (0.47) KMT2AGPR119STSMMP13MEN1
SCHEMBL216692 0.76 GPR119 (0.58) KMT2AGPR119STSMMP13MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3083591-B1 N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE MERCK PATENT GMBH (DE) 2018-01-03 EP disclosed
US-9751861-B2 N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase MERCK PATENT GMBH (DE) 2017-09-05 US disclosed
US-20160311798-A1 N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE MERCK PATENT GMBH (DE) 2016-10-27 US disclosed
EP-3083591-A1 N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE Merck Patent GmbH (DE) 2016-10-26 EP disclosed
WO-2015090496-A1 N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE MERCK PATENT GMBH (DE) 2015-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160311798-A1 N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE PDK1, PDK3, PDK2 KMT2A 765/4885GPR119 1059/4885STS 3406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.